**Winter 2013**

**In This Issue:**
American Society of Hematology (ASH), American Society for Therapeutic Radiation Oncology (ASTRO), San Antonio Breast Cancer Symposium (SABCS), Chicago Multidisciplinary Symposium in Thoracic Oncology, Society for Neuro Oncology (SNO), ASCO, EORTC and NCI - Markers in Cancer, International Society for Quality of Life Research (ISOQOL) and Others

**Cooperative Group Abstracts:**
- Breast Cancer
- CNS Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecologic Cancer
- Head and Neck Cancer
- Leukemia, Myelodysplasia, and Transplantation
- Lung Cancer
- Lymphoma and Plasma Cell Disorders
- Melanoma/Skin Cancers
- Other Cancer
- NCI/CTEP Abstracts & Activities:
  - DCTD/DCP Abstracts

---

**Research Highlights in this Issue:**

**NSABP-B-18, NSABP-B-27:** A meta-analysis including 12 randomized controlled trials of neoadjuvant systemic therapy in breast cancer was conducted and showed:

- ypT0, ypN0: Absence of invasive cancer in the breast and axillary nodes, and absence of ductal carcinoma in situ (DCIS) (13%)
- ypT0/is, ypN0: Absence of invasive cancer in the breast and axillary nodes; DCIS is allowed (18%)
- ypT0/is: Absence of invasive cancer in the breast regardless of nodal involvement; DCIS is allowed (22%)

The achievement of a pathologic CR was positively associated with more favorable long-term outcomes, regardless of whether DCIS was present or absent. For consistency, a standard pathologic CR definition was recommended for use in future trials, preferably ypT0ypN0 or ypT0/isypN0.

Unfortunately, the magnitude of pathologic CR improvement predicting long-term clinical benefit could not be established, raising questions as to the potential utility of pCR as a surrogate endpoint for neoadjuvant clinical trials in breast cancer. On March 22, 2013, the FDA is conducting a workshop to discuss the potential of pCR in drug development.

**E2902:** In older patients with relapsed/refractory acute myelogenous leukemia in remission, administration of tipifarnib was found in an unplanned analysis to be associated with improved survival at 10 months (70% with tipifarnib versus 48% with observation). Interestingly the differences in relapse rate was not different between the treatment arms. These findings may support clinical investigations of treatment strategies that do not depend on maintaining a complete response but that do have clinical benefit with improved survival.
Breast Cancer

**ACOSOG/Alliance**


Protocol(s): ACOSOG-Z1071


Protocol(s): ACOSOG-Z1031


Protocol(s): ACOSOG-Z0010

**CALGB/Alliance**


Protocol(s): CALGB-49907


Protocol(s): CALGB-150007, CALGB-150012


Protocol(s): CLB-9741
http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P2-05-01?rss=1
Other Participant(s): ACRIN
Protocol(s): ACRIN-6657, CALGB-150007, CALGB-150012

http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P3-04-01?rss=1
Protocol(s): CALGB-150007, CALGB-150012

http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/P3-04-02?rss=1
Protocol(s): CALGB-150007, CALGB-150012

ECOG

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-17-01?sid=4a4625fa-5383-495e-9768-69dbd4a21da8
Other Participant(s): CTSU
Protocol(s): E5103

NCCTG/Alliance

Protocol(s): NCCTG-N0937

Protocol(s): NCCTG N9831-ICSC
Protocol(s): NCCTG N9831-ICSC

NCIC Clinical Trials Group

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P1-13-01?sid=ef4aca18-18e3-45bc-9a8c-4537aeb2160c
Other Participant(s): CTSU
Protocol(s): NCIC-MA.21

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P2-13-02?sid=e455469a-7430-4ba5-b431-ec2fa94c6b9
Protocol(s): NCIC-MA.27

NSABP

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S3-2?sid=8a0a9401-71f0-4506-ba86-c712040e41a8
Other Participant(s): CTSU
Protocol(s): NSABP-B-37

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT1-2-01?sid=c9ad9cb6-2528-4c5f-8e79-ef177a3f91a2
Other Participant(s): CTSU
Protocol(s): NSABP-B-43
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S1-11?sid=2bed17a3-2774-42fd-a123-073f4ebde791
Protocol(s): NSABP-B-18, NSABP-B-27

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=125&abstractID=102893
Protocol(s): NSABP-B-28

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S1-10?sid=eff18f6e-c79a-4034-ab62-8e281a134195
Protocol(s): NSABP-B-28

Other Participant(s): NCCTG/Alliance
Protocol(s): NCCTG N9831-ICSC, NSABP-B-31

http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P6-07-06?sid=8a0a9401-7f10-4506-ba86-c71204e41a8
Other Participant(s): CTSU
Protocol(s): NSABP-B-37
**RTOG**

Protocol(s): RTOG-9804

**SWOG**

[http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT2-2-04?sid=f0efaef4-ce85-4d8d-8fb1-74bf93a69880](http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT2-2-04?sid=f0efaef4-ce85-4d8d-8fb1-74bf93a69880)  
Other Participant(s): CTSU, NSABP  
Protocol(s): S1207

Protocol(s): SWOG-S1200

**CNS Cancer**

**RTOG**

Protocol(s): RTOG-90-03

Protocol(s): RTOG-0614

Other Participant(s): NCCTG/Alliance  
Protocol(s): INT-0149
http://www.redjournal.org/article/S0360-3016(12)00957-1/fulltext
Protocol(s): RTOG-0525

http://neuro-oncology.oxfordjournals.org/content/14/suppl_6/vi65.full
Protocol(s): RTOG-0929

http://neuro-oncology.oxfordjournals.org/content/14/suppl_6/vi65.full
Protocol(s): RTOG-0131

http://neuro-oncology.oxfordjournals.org/content/14/suppl_6/vi61.full
Protocol(s): RTOG-0614

Gastrointestinal Cancer

NCCTG/Alliance

Protocol(s): N0147

NSABP

Protocol(s): NSABP-C-07
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=127&abstractID=103629
Other Participant(s): CTSU
Protocol(s): NSABP-C-08

RTOG

http://www.redjournal.org/article/S0360-3016(12)01318-1/fulltext
Protocol(s): RTOG-98-11

Protocol(s): RTOG-97-04

http://www.redjournal.org/article/S0360-3016(12)01017-6/fulltext
Protocol(s): RTOG-97-04

Genitourinary Cancer

RTOG

Protocol(s): RTOG-0126

http://www.redjournal.org/article/S0360-3016(12)01184-4/fulltext
Protocol(s): RTOG-92-02, RTOG-99-02
http://www.redjournal.org/article/S0360-3016(12)01919-0/fulltext
Protocol(s): RTOG-0518

http://www.redjournal.org/article/S0360-3016%2812%2901190-X/fulltext
Protocol(s): RTOG-92-02

http://www.redjournal.org/article/S0360-3016(12)01158-3/fulltext
Protocol(s): RTOG-0233, RTOG-88-02, RTOG-89-03, RTOG-95-06, RTOG-97-06, RTOG-99-06

http://www.redjournal.org/article/S0360-3016(12)00086-8/fulltext
Protocol(s): RTOG-94-08, RTOG-96-01

http://www.redjournal.org/article/S0360-3016(12)00987-X/fulltext
Protocol(s): RTOG-0126

SWOG

http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&confID=127&abstractID=103697
Protocol(s): S0421
Gynecologic Cancer

**RTOG**


[http://www.redjournal.org/article/S0360-3016%2812%2900996-0/fulltext](http://www.redjournal.org/article/S0360-3016%2812%2900996-0/fulltext)

Protocol(s): RTOG-0418


Protocol(s): RTOG-0417

Head and Neck Cancer

**NCCTG/Alliance**


[http://download.journals.elsevierhealth.com/pdfs/journals/0360-3016/PIIS0360301612037728.pdf](http://download.journals.elsevierhealth.com/pdfs/journals/0360-3016/PIIS0360301612037728.pdf)

Protocol(s): NCCTG-N09C6

**RTOG**


[http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3021&sKey=98fd346d-1d0c-475f-9c13-6c888c99f248&ckey=6eb6508-6559-4acf-8718-4b85798b0db3&mkey={1514526B-FDA6-42BC-948B-C58023F5A94F}](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3021&sKey=98fd346d-1d0c-475f-9c13-6c888c99f248&ckey=6eb6508-6559-4acf-8718-4b85798b0db3&mkey={1514526B-FDA6-42BC-948B-C58023F5A94F})

Protocol(s): RTOG-99-11


Protocol(s): RTOG-99-03
Leukemia, Myelodysplasia, and Transplantation

**CALGB/Alliance**


http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/44

Protocol(s): CALGB-10503


http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/230

Protocol(s): CALGB-100103


http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/816

Protocol(s): CALGB-10001


http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1293

Protocol(s): CALGB-20202, CALGB-8461, CALGB-9665

**ECOG**


http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1875

Protocol(s): E1900, E2995, E3999

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2489?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=2489&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT

Other Participant(s): SWOG
Protocol(s): E3999, S0112, S0301, S9031-S9126-S9333-S9500


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2481?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=2481&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Protocol(s): E1900


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/528?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=+528&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT

Protocol(s): E2993

Laurie CC, Laurie CA, Fridley B, Carlson E, Smoley S, Flinn IW, Tallman MS, Paietta EM, Weinsilboum R, Kay NE, Shanafelt TD: Clonal chromosomal anomalies similar to CLL and other hematologic malignancies can be found in "normal" individuals. Blood 2012; 120(21): Abst. 873.

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/873?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=873&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Other Participant(s): CALGB/Alliance, SWOG
Protocol(s): E2997


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/676?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=676&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Other Participant(s): CTSU
Protocol(s): E2902


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/663?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=663&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Protocol(s): E2993
http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/294?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=294&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Protocol(s): E2993

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/132?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=132&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Other Participant(s): CALGB/Alliance, SWOG
Protocol(s): E1900, E3489, EST-3483

NCCTG/Alliance

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3928?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=3928&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Protocol(s): NCCTG-N1087

OTHER

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3535?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=swog&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
Other Participant(s): CALGB/Alliance, ECOG, SWOG
Protocol(s): C10403

SWOG

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2603?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=s0910&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
Protocol(s): S0910


Lung Cancer

**CALGB/Alliance**


Protocol(s): CALGB-150607

ECOG

Other Participant(s): CTSU
Protocol(s): E4599

NCCTG/Alliance

Protocol(s): NCCTG-N0028

RTOG

Protocol(s): RTOG-1106

Protocol(s): RTOG-1106

Protocol(s): RTOG-1106
http://www.redjournal.org/article/S0360-3016%2812%2901113-3/fulltext  
Protocol(s): RTOG-0214

http://www.redjournal.org/article/S0360-3016%2812%2901018-8/fulltext  
Other Participant(s): ACRIN  
Protocol(s): RTOG-1106

http://www.redjournal.org/article/S0360-3016%2812%2901278-3/fulltext  
Protocol(s): RTOG-0236

SWOG

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=af961e0d-edd2-4b48-a08a-86579c4fa1a&cKey=d38a7954-1a2e-4fcd-858b-7881af35f1c&mKey=%7bE968B2E9-DA03-40BD-9B81-7EFE158EB9C1%7d  
Protocol(s): S0533

http://www.redjournal.org/article/S0360-3016%2812%2901346-6/fulltext  
Protocol(s): S0533
Lymphoma and Plasma Cell Disorders

CALGB/Alliance

http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/3696
Protocol(s): CALGB-50501

http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/301
Protocol(s): CALGB-50502

ECOG

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3705?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=3705&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Other Participant(s): CALGB/Alliance, SWOG
Protocol(s): E1496, E4494

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/153?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=153&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Protocol(s): E1405

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4079?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=4079&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Other Participant(s): CTSU
Protocol(s): E3A06

http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/687?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=687&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Protocol(s): E3404


NCIC Clinical Trials Group


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/548?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=klimm&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT

Other Participant(s): ECOG
Protocol(s): JHD06

SWOG


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/543?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=543&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Protocol(s): S9704


http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2712?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=2712&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Protocol(s): S0016, S9800, S9911

Other Cancer

ECOG


http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=126&abstractID=104199

Protocol(s): E2Z02


https://smdm.confex.com/smdm/2012az/webprogram/Paper7314.html

Other Participant(s): CTSU
Protocol(s): E5103
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/S1-11?sid=2bed17a3-2774-42fd-a123-073f4ebde791


Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.